GSK and Flagship Pioneering Announce $720M Collaboration to Develop Transformational Medicines and Vaccines
- Jul 31, 2024
- 1 min read
London and Cambridge, MA, July 29, 2024 (PRNewswire) -- GSK and Flagship Pioneering are collaborating to discover and develop transformational medicines and vaccines, beginning with respiratory and immunology. The initial exploration phase will be funded with a joint $150 million to identify promising concepts. Flagship and its bioplatform companies could receive up to $720 million per acquired program in milestones and royalties.
Read full article here.
Comments